New name, new board, new focus: AltruBio relaunches with $63M series A

AltruBio would like to reintroduce itself. After shifting from oncology to immunology, swapping out the board and completing a name change, the biotech is relaunching with a $63 million series A funding round.

"We put aside our oncology product to be able to 100% focus on this first in class and novel molecule we have," said CEO Judy Chou, Ph.D., speaking of the immune checkpoint agonist antibody neihulizumab.